CytoDyn (CYDY) Cash & Equivalents (2010 - 2026)

CytoDyn's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• Quarterly Cash & Equivalents fell 4.54% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $15.7 million (down 4.54% YoY) and the FY2025 annual result came in at $11.9 million, up 77.55% from the prior year.
• Cash & Equivalents was $15.7 million for Q1 2026 at CytoDyn, up from $5.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $24.9 million in Q3 2024 and bottomed at $147000.0 in Q4 2023.
• A 5-year average of $8.1 million and a median of $5.1 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 97.75% — and 2024, when it soared 14413.61%.
• CytoDyn's Cash & Equivalents stood at $200000.0 in 2022, then slipped by 26.5% to $147000.0 in 2023, then surged by 14413.61% to $21.3 million in 2024, then sank by 76.65% to $5.0 million in 2025, then soared by 214.23% to $15.7 million in 2026.
• Business Quant data shows CYDY's Cash & Equivalents at $15.7 million in Q1 2026, $5.0 million in Q4 2025, and $9.3 million in Q3 2025.